title: PI3K is required for the physical interaction and functional inhibition of NF-κB by β-catenin in colorectal cancer cells.
abstract: Activation of β-catenin and PI3K pathways are crucial for the oncogenesis of colorectal cancer (CRC). It remains controversial whether these two pathways function independently or cooperatively in the development and progression of CRC. We showed previously that β-catenin inhibited NF-κB activation by interacting with p65 and this inhibitory interaction involved an unidentified cellular protein. In this study, we found that the PI3K effect on NF-κB activity is dependent on the level of β-catenin in CRC cells. PI3K promoted NF-κB activity in the β-catenin-low RKO cells; whereas it inhibited NF-κB activity in the β-catenin-high HCT116, DLD-1, and SW480 cells. We showed that PI3K is required for the physical interaction and functional inhibition of NF-κB by β-catenin. Inhibition of PI3K released NF-κB suppression in β-catenin-high CRC cells, which conferred these cells with susceptibility to TNFα- and Fas-induced apoptosis. This is consistent with the observation showing that the level of β-catenin and activated Akt are both inversely correlated with the expression of Fas, a downstream target of NF-κB, in CRC specimens. Mechanistically, the PI3K subunit p85 formed a complex with β-catenin and NF-κB. Inhibition of PI3K disrupted the complex formation, leading to NF-κB activation. Our study not only provides new insight into the cross-talk among PI3K, β-catenin and NF-κB signaling pathways but also indicates that targeting PI3K may yield therapeutic efficacy in treating β-catenin-high CRC.
authors.affiliation: Department of Immunology, Nankai University School of Medicine, Tianjin 300071, China.
authors.forename: Jingyi
authors.initials: J
authors.lastname: Liu
authors.forename: Yueling
authors.initials: Y
authors.lastname: Liao
authors.forename: Kewei
authors.initials: K
authors.lastname: Ma
authors.forename: Yonglu
authors.initials: Y
authors.lastname: Wang
authors.forename: Guoxiang
authors.initials: G
authors.lastname: Zhang
authors.forename: Rongcun
authors.initials: R
authors.lastname: Yang
authors.forename: Jiong
authors.initials: J
authors.lastname: Deng
mesh_terms: D000730:Androstadienes / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002867:Chromones / Q000494:pharmacology; D058543:Class Ia Phosphatidylinositol 3-Kinase / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D045325:HCT116 Cells; D006801:Humans; D008856:Microscopy, Fluorescence; D009025:Morpholines / Q000494:pharmacology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D011485:Protein Binding / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D000077191:Wortmannin; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism*; D019014:fas Receptor / Q000378:metabolism
chemical_list: D000730:Androstadienes; D002867:Chromones; D009025:Morpholines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D051176:beta Catenin; D019014:fas Receptor; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D058543:Class Ia Phosphatidylinositol 3-Kinase; D051057:Proto-Oncogene Proteins c-akt; D000077191:Wortmannin